Understanding the serological responses to COVID-19 vaccination in children with history of MIS-C could inform vaccination recommendations. We prospectively enrolled seven children hospitalized with MIS-C and measured SARS-CoV-2 binding IgG antibodies to spike protein variants longitudinally pre- and post-Pfizer-BioNTech BNT162b2 primary series COVID-19 vaccination. We found that SARS-CoV-2 variant cross-reactive IgG antibodies variably waned following acute MIS-C, but were significantly boosted with vaccination and maintained for up to 3 months. We then compared post-vaccination binding, pseudovirus neutralizing, and functional antibody-dependent cell-mediated cytotoxicity (ADCC) titers to the reference strain (Wuhan-hu-1) and Omicron variant (B.1.1.529) among previously healthy children (n = 16) and children with history of MIS-C (n = 7) or COVID-19 (n = 8). Despite the breadth of binding antibodies elicited by vaccination in all three groups, pseudovirus neutralizing and ADCC titers were significantly reduced to the Omicron variant.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Evan J. Anderson reports a relationship with AbbVie Inc that includes: consulting or advisory. Evan J. Anderson reports a relationship with Medscape LLC that includes: consulting or advisory. Evan J. Anderson reports a relationship with Pfizer Inc that includes: consulting or advisory and funding grants. Evan J. Anderson reports a relationship with Sanofi Pasteur Inc that includes: board membership, consulting or advisory, and funding grants. Evan J. Anderson reports a relationship with AstraZeneca Medimmune that includes: funding grants. Evan J. Anderson reports a relationship with Regeneron Pharmaceuticals Inc that includes: funding grants. Evan J. Anderson reports a relationship with PaxVax that includes: funding grants. Evan J. Anderson reports a relationship with GlaxoSmithKline USA that includes: consulting or advisory and funding grants. Evan J. Anderson reports a relationship with Merck & Co Inc that includes: funding grants. Evan J. Anderson reports a relationship with Novavax Inc that includes: funding grants. Evan J. Anderson reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory and funding grants. Evan J. Anderson reports a relationship with Micron Biomedical that includes: funding grants. Evan J. Anderson reports a relationship with Kentucky BioProcessing Inc that includes: board membership. Christina A. Rostad reports a relationship with Biofire Diagnostics Inc that includes: funding grants. Christina A. Rostad reports a relationship with GlaxoSmithKline USA that includes: funding grants. Christina A. Rostad reports a relationship with AstraZeneca Medimmune that includes: funding grants. Christina A. Rostad reports a relationship with Micron Biomedical that includes: funding grants. Christina A. Rostad reports a relationship with Novavax Inc that includes: funding grants. Christina A. Rostad reports a relationship with Merck & Co Inc that includes:. Christina A. Rostad reports a relationship with PaxVax that includes: funding grants. Christina A. Rostad reports a relationship with Pfizer Inc that includes: funding grants. Christina A. Rostad reports a relationship with Regeneron Pharmaceuticals Inc that includes: funding grants. Christina A. Rostad reports a relationship with Sanofi Pasteur Inc that includes: funding grants. Evan J. Anderson reports a relationship with WIRB-Copernicus Group Inc that includes: board membership. Evan J. Anderson reports a relationship with ACI Clinical that includes: board membership. Christina A. Rostad has patent Chimeric RSV, Immunogenic Compositions, and Methods of Use. with royalties paid to Meissa Vaccines, Inc.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)